体育博彩

Akeso was included in the “Chinese Antibody Drug Companies Innovation TOP 30” by “2020 Chinese Biopharma Companies Innovation TOP 100 Series Lists”
2021-09-26
Akeso was included in the “Chinese Antibody Drug Companies Innovation TOP 30” by “2020 Chinese Biopharma Companies Innovation TOP 100 Series Lists”
New Drug Application for Cadonilimab (PD-1/CTLA-4 Bi-Specific Antibody) for the Treatment of Relapsed or Metastatic Cervical Cancer Accepted by NMPA
2021-09-24
New Drug Application for Cadonilimab (PD-1/CTLA-4 Bi-Specific Antibody) for the Treatment of Relapsed or Metastatic Cervical Cancer Accepted by NMPA
2021 CSCO | Latest Results of Two Phase II Clinical Studies of Akeso’s PD-1/VEGF Bispecific Antibody (AK112) for Treatment of Lung Cancer and Ovarian Cancer
2021-09-23
2021 CSCO | Latest Results of Two Phase II Clinical Studies of Akeso’s PD-1/VEGF Bispecific Antibody (AK112) for Treatment of Lung Cancer and Ovarian Cancer
Akeso Publishes Updated Results of a Phase II Study of Penpulimab Monoclonal Antibody for Treatment of Metastatic NPC with Progression after Two or More Lines of Chemotherapy at ESMO 2021
2021-09-19
Akeso Publishes Updated Results of a Phase II Study of Penpulimab Monoclonal Antibody for Treatment of Metastatic NPC with Progression after Two or More Lines of Chemotherapy at ESMO 2021
Akeso’s Latest Updates of a Phase Ib/II Trial of AK104 (PD-1/CTLA-4 Bi-Specific Antibody) in Combination with Anlotinib in Patients with PD-L1 Positive and Anti-PD-1/L1 Resistant Advanced NSCLC at ESMO 2021
2021-09-19
Akeso’s Latest Updates of a Phase Ib/II Trial of AK104 (PD-1/CTLA-4 Bi-Specific Antibody) in Combination with Anlotinib in Patients with PD-L1 Positive and Anti-PD-1/L1 Resistant Advanced NSCLC at ESMO 2021
Oral Presentation of Mechanism Study of IgG1 Isotype Anti-PD-1 Monoclonal Antibody Penpulimab at ESMO 2021 by Akeso’s CSO, Dr. Baiyong Li
2021-09-19
Oral Presentation of Mechanism Study of IgG1 Isotype Anti-PD-1 Monoclonal Antibody Penpulimab at ESMO 2021 by Akeso’s CSO, Dr. Baiyong Li
Akeso, Inc. Works with Pfizer to Conduct a Clinical Research of Cadonilimab (Bi-specific Antibody) with Combination of Axitinib for the First-line Treatment of Advanced / Metastatic Renal Clear Cell Carcinoma
2021-08-27
Akeso, Inc. Works with Pfizer to Conduct a Clinical Research of Cadonilimab (Bi-specific Antibody) with Combination of Axitinib for the First-line Treatment of Advanced / Metastatic Renal Clear Cell Carcinoma
Akeso’s PD-1/CTLA-4 Bi-Specific Antibody Obtained Approval from the CDE to Submit NDA and has been Granted Priority Review Designation
2021-08-24
Akeso’s PD-1/CTLA-4 Bi-Specific Antibody Obtained Approval from the CDE to Submit NDA and has been Granted Priority Review Designation
New PD-1 Monoclonal Antibody 安尼可® (Penpulimab) Officially for Sale, First Prescriptions Made Nationwide
2021-08-23
New PD-1 Monoclonal Antibody 安尼可® (Penpulimab) Officially for Sale, First Prescriptions Made Nationwide
Akeso Shipped off its First Batch of Penpulimab Monoclonal Antibody Injection (安尼可®)
2021-08-21
Akeso Shipped off its First Batch of Penpulimab Monoclonal Antibody Injection (安尼可®)
Akeso’s Latest Updates on the Clinical Trials of Cadonilimab and 安尼可 ® (Penpulimab) will be Published at ESMO 2021
2021-08-09
Akeso’s Latest Updates on the Clinical Trials of Cadonilimab and 安尼可 ® (Penpulimab) will be Published at ESMO 2021
Penpulimab Monoclonal Antibody (PD-1) Obtains Marketing Approval in China
2021-08-05
Penpulimab Monoclonal Antibody (PD-1) Obtains Marketing Approval in China
线上正规博彩 澳门新葡京赌场 mg冰球突破豪华版下载 太阳城在线娱乐 博鱼体育